Douglas Woodruff
Psychiatry · Baltimore, MDNPI 1972779023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,208 and has fallen 76.0% since, to $290 in 2025. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$796
- Otsuka America Pharmaceutical, Inc.$538
- Johnson & Johnson$523
- Sunovion Pharmaceuticals Inc.$434
- Supernus Pharmaceuticals, Inc.$312
- Takeda Pharmaceuticals U.S.A., Inc.$306
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,360100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $796 |
| Otsuka America Pharmaceutical, Inc. | 7 | $538 |
| Johnson & Johnson | 10 | $523 |
| Sunovion Pharmaceuticals Inc. | 17 | $434 |
| Supernus Pharmaceuticals, Inc. | 6 | $312 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $306 |
| Adlon Therapeutics L.p. | 14 | $209 |
| Bausch Health US, LLC | 7 | $149 |
| Lundbeck LLC | 7 | $141 |
| Corium, LLC | 6 | $130 |
| Indivior Inc. | 5 | $117 |
| Eisai Inc. | 6 | $113 |
| Almatica Pharma LLC | 3 | $87 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $84 |
| Tris Pharma Inc | 3 | $74 |
| Sage Therapeutics, LLC | 1 | $71 |
| Merck | 5 | $65 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Braeburn Inc. | 1 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,360 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 12 | $4,570 |
| Lurasidone Hcl | 12 | $2,340 |
| Bupropion XlBupropion Hcl | 89 | $1,906 |
| Atomoxetine Hcl | 23 | $1,617 |
| Duloxetine Hcl | 96 | $1,539 |
| Trazodone Hcl | 76 | $921 |
| Methylphenidate Hcl | 17 | $591 |
| Oxcarbazepine | 16 | $577 |
| Buspirone Hcl | 55 | $500 |
| Alprazolam | 22 | $395 |
| Aripiprazole | 17 | $333 |
| Quetiapine Fumarate | 46 | $325 |
| Fluoxetine Hcl | 21 | $278 |
| Escitalopram Oxalate | 37 | $270 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $233 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.